For US Healthcare Professionals
Important Safety Information Prescribing Information
Important Safety Information Prescribing Information
    Page: /    link

{{userName}}

{{userEmailAddress}}

{{User.phone}}

REQUEST A MEETING

{{userName}}

{{userEmailAddress}}

{{User.phone}}

Information and Resources

Visit our full website to learn more about
AREXVY and access valuable resources.

Visit

Educational Events

Register for an upcoming educational webinar
about AREXVY.

Register

Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

Important Safety Information

  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
  • The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
  • Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see full Prescribing Information.